Oxford BioMedica
Discover Realise

Our licensees

Emergent BioSolutions

Products partnered:
PrimeBoost

Oxford BioMedica has granted Emergent BioSolutions non-exclusive rights to its PrimeBoost technology patents and a sub-licence under poxvirus patents licensed to the Company for the development and commercialisation of vaccines and therapeutics targeting eight infectious diseases, including tuberculosis.

www.emergentbiosolutions.com


Molmed

Products/technology licensed:
Oxford BioMedica has licensed its retroviral ex vivo gene delivery technology to Milan-based biotechnology company, MolMed. MolMed is utilising the technology in its TK therapy for the prevention of transplant rejection in patients with acute leukaemia receiving haematopoietic stem cell transplantation from a partially compatible family donor. MolMed is conducting a Phase III trial of the TK therapy.

www.molmed.com


Sigma-Aldrich

Products/technology licensed:
Oxford BioMedica has a strategic alliance with Sigma-Aldrich for the development and marketing of research products based on Oxford BioMedica’s LentiVector® gene delivery technology.

www.sigmaaldrich.com


Biogen Idec

Products/technology licensed:
Oxford BioMedica has granted a non-exclusive licence to its LentiVector® gene delivery technology for use in research to Biogen Idec.

www.biogenidec.com


GlaxoSmithKline (GSK)

Products/technology licensed:
Oxford BioMedica has granted a non-exclusive licence to its LentiVector® gene delivery technology for use in research to GSK. On 28 October 2015, GlaxoSmithKline PLC (GSK) exercised an option to obtain a non-exclusive licence for two orphan disease indications under Oxford BioMedica's LentiVector® platform technology patents.

www.gsk.com


Merck & Co

Products/technology licensed:
Oxford BioMedica has granted a non-exclusive licence to its LentiVector® gene delivery technology for use in research to Merck & Co.

www.merck.com


Pfizer

Products/technology licensed:
Oxford BioMedica has granted a non-exclusive licence to its LentiVector® gene delivery technology for use in research to Pfizer.

www.pfizer.com

 

 

Facts

Two

We have two technology platforms: the LentiVector® platform gene delivery system (ideal for targeting chronic disease) and the 5T4 tumour antigen platform (anti-cancer therapy)


500

The LentiVector® platform technology is protected by a comprehensive patent portfolio of around 60 patent families including over 500 issued patents


Research

We are world leaders in the development of lentiviral vectors and our scientists are named authors on multiple publications